步长制药: 山东步长制药股份有限公司关于注销回购股份暨减少注册资本通知债权人的公告

Core Viewpoint - Shandong Buchang Pharmaceutical Co., Ltd. is notifying creditors about the cancellation of repurchased shares and the reduction of registered capital, following the approval of relevant board meetings and resolutions [1][2][3]. Group 1: Share Repurchase and Capital Reduction - The company approved a share repurchase plan on December 13, 2023, with a total fund amount between 180 million and 360 million yuan, at a maximum price of 24 yuan per share [1]. - On June 14, 2024, the board increased the repurchase amount to between 360 million and 720 million yuan, while maintaining other terms of the original plan [1]. - As of November 6, 2024, the company completed the share repurchase through centralized bidding [1]. - On April 25, 2025, the company decided to change the purpose of 44,853,573 repurchased shares to "reduce registered capital" [2]. - A second resolution on May 26, 2025, involved changing the purpose of an additional 6,620,630 repurchased shares to "reduce registered capital" [3]. - Following these actions, the total number of shares will decrease from 1,106,042,645 to 1,054,568,442 shares [3]. Group 2: Creditor Notification - The company is notifying creditors that the cancellation of repurchased shares will lead to a reduction in registered capital, as required by relevant laws and regulations [4]. - Creditors have 45 days from the announcement date to claim their debts or request guarantees [4]. - The required documents for debt claims include contracts and other proof of the debt relationship, with specific requirements for both corporate and individual creditors [5].